7-OH-DPAT

7-OH-DPAT
Nazivi
	IUPAC naziv 7-Hidroksi-N,N-dipropil-2-aminotetralin
	Sistemski IUPAC naziv 7-(Dipropilamino)-5,6,7,8-tetrahidronaftalen-2-ol
Identifikacija
CAS broj	74938-11-7 ;
3D model (Jmol)	interaktivna slika; interaktivna slika;
Abrevijacija	7-OH-DPAT
ChemSpider	1182 ; 5036175 (R) ;
MeSH	7-Hydroxy-2-N,N-dipropylaminotetralin
PubChem C ID	1219; 6603867 (R); 23928184 (S);
	SMILES CCCN(CCC)C1CCc2ccc(O)cc2C1; CCCN(CCC)C1CCC2=C(C1)C=C(O)C=C2; ; ; ; ;
Svojstva
Hemijska formula	C16H25NO
Molarna masa	247,38 g·mol−1
log P	3,653
Kiselost (pKa)	10,389
Baznost (pKb)	3,608
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

7-OH-DPAT je sintetičko jedinjenje koje deluje kao agonist dopaminskog receptora sa umerenom selektivnošću za D₃ receptorski podtip,^[4]^[5]^[6] i sa niskim afinitetom za serotoninske receptore, za razliku od njegovog strukturnog izomera 8-OH-DPAT.^[7]^[8]^[9]

Reference уреди

^ ^а ^б „7-hydroxy-2-N,N-dipropylaminotetralin - PubChem Public Chemical Database”. The PubChem Project. USA: National Center for Biotechnology Information.
^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS (1987). „Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin”. Naunyn-Schmiedeberg's Archives of Pharmacology. 336 (5): 494—501. PMID 2830544.
^ Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992). „Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin”. Proceedings of the National Academy of Sciences of the United States of America. 89 (17): 8155—9. PMC 49875  . PMID 1518841. doi:10.1073/pnas.89.17.8155.
^ Lévesque D (1996). „Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions?”. Biochemical Pharmacology. 52 (4): 511—8. PMID 8759022. doi:10.1016/0006-2952(96)00239-0.
^ Arvidsson LE, Johansson AM, Hacksell U, Nilsson JL, Svensson K, Hjorth S, Magnusson T, Carlsson A, Andersson B, Wikström H (1987). „(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist”. Journal of Medicinal Chemistry. 30 (11): 2105—9. PMID 2959776. doi:10.1021/jm00394a029.
^ Malmberg A, Nordvall G, Johansson AM, Mohell N, Hacksell U (1994). „Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors”. Molecular Pharmacology. 46 (2): 299—312. PMID 8078492.
^ Eltayb A, Lindblom S, Oerther S, Ahlenius S (2001). „Additive hypothermic effects of the 5-HT1A receptor agonist 8-OH-DPAT and the dopamine D2/3 receptor agonist 7-OH-DPAT in the rat”. Acta Physiologica Scandinavica. 172 (3): 205—9. PMID 11472307. doi:10.1046/j.1365-201x.2001.00858.x.

Vidi još уреди

[Pubchem-1] а ^б „7-hydroxy-2-N,N-dipropylaminotetralin - PubChem Public Chemical Database”. The PubChem Project. USA: National Center for Biotechnology Information.

[2] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[3] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[pmid2830544-4] Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS (1987). „Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin”. Naunyn-Schmiedeberg's Archives of Pharmacology. 336 (5): 494—501. PMID 2830544.

[pmid1518841-5] Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992). „Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin”. Proceedings of the National Academy of Sciences of the United States of America. 89 (17): 8155—9. PMC 49875  . PMID 1518841. doi:10.1073/pnas.89.17.8155.

[pmid8759022-6] Lévesque D (1996). „Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions?”. Biochemical Pharmacology. 52 (4): 511—8. PMID 8759022. doi:10.1016/0006-2952(96)00239-0.

[pmid2959776-7] Arvidsson LE, Johansson AM, Hacksell U, Nilsson JL, Svensson K, Hjorth S, Magnusson T, Carlsson A, Andersson B, Wikström H (1987). „(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist”. Journal of Medicinal Chemistry. 30 (11): 2105—9. PMID 2959776. doi:10.1021/jm00394a029.

[pmid8078492-8] Malmberg A, Nordvall G, Johansson AM, Mohell N, Hacksell U (1994). „Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors”. Molecular Pharmacology. 46 (2): 299—312. PMID 8078492.

[pmid11472307-9] Eltayb A, Lindblom S, Oerther S, Ahlenius S (2001). „Additive hypothermic effects of the 5-HT1A receptor agonist 8-OH-DPAT and the dopamine D2/3 receptor agonist 7-OH-DPAT in the rat”. Acta Physiologica Scandinavica. 172 (3): 205—9. PMID 11472307. doi:10.1046/j.1365-201x.2001.00858.x.

[4]

[5]

[6]

[7]

[8]

[9]

[1]

[2]

[3]